(December 11, 2020, 12:22 PM EST) -- BOSTON — A biopharmaceutical company and its CEO violated federal securities laws by misrepresenting the success of Phase 2b clinical trial results for the drug maker’s schizophrenia treatment drug, as well as the expected approval of a new drug application (NDA) by the U.S. Food and Drug Administration based on clinical trial results, a shareholder alleges in a Dec. 8 securities class action complaint filed in Massachusetts federal court (Nathan McCoy v. Minerva Neurosciences Inc., et al., No. 20-12176, D. Mass.)....